MedTrace Logo

Neurofilament Light Chain in Amyotrophic Lateral Sclerosis

NCT06201650 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2024-01-11

No results posted yet for this study

Summary

This study assesses the performance of serum neurofilament light chain (sNfL) in amyotrophic lateral sclerosis (ALS) in a wide range of disease courses, in terms of ALS progression, disease duration, and tracheostomy invasive ventilation (TIV). The aim of the research project is to investigate the correlation between NfL serum concentration and the natural course of the disease, the ALS progression rate, and specific phenotypes of ALS. Furthermore, the performance of NfL as a therapeutic biomarker will be studied. A systematic analysis of the NfL serum concentration in a cohort of 3,000 ALS patients using the Single Molecule Analysis method (SIMOA) will be performed. This analysis is carried out as a multi-center study.

Conditions

Interventions

DIAGNOSTIC_TEST

Neurofilament light chain

Neurofilament light chain as biomarker for amyotrophic lateral sclerosis

Sponsors & Collaborators

  • Boris Canessa ALS Stiftung

    collaborator UNKNOWN

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Thomas Meyer, MD · Charite University, Berlin, Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-11
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06201650 on ClinicalTrials.gov